Peter Nigel Leigh

Peter Nigel Leigh's AcademicInfluence.com Rankings

Peter Nigel Leigh

Biology

#13141

World Rank

#16669

Historical Rank

Neuroscience

#2260

World Rank

#2321

Historical Rank

biology Degrees

Download Badge

Biology

Peter Nigel Leigh's Degrees

Bachelors Biology University of California, Berkeley

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Peter Nigel Leigh Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Peter Nigel Leigh's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis (2008) (2389)
Mutations in FUS, an RNA Processing Protein, Cause Familial Amyotrophic Lateral Sclerosis Type 6 (2009) (2360)
Fronto-striatal cognitive deficits at different stages of Parkinson's disease. (1992) (884)
Motor neuron disease. (1994) (515)
Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis (2009) (508)
Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis (2016) (424)
Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS) (2000) (406)
Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. (2007) (390)
Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. (2001) (372)
Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis (2009) (358)
Ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis. Morphology, distribution, and specificity. (1991) (346)
Amyotrophic lateral sclerosis (2009) (342)
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study (2008) (305)
Ubiquitin deposits in anterior horn cells in motor neurone disease (1988) (293)
Reorganization of cortical blood flow and transcranial magnetic stimulation maps in human subjects after upper limb amputation. (1994) (285)
Frontal lobe dysfunction in amyotrophic lateral sclerosis. A PET study. (1996) (276)
Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration (2008) (274)
Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction. (1994) (272)
Cortical function in amyotrophic lateral sclerosis. A positron emission tomography study. (1993) (269)
Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study (2014) (266)
The relationship between abnormalities of cognitive function and cerebral activation in amyotrophic lateral sclerosis. A neuropsychological and positron emission tomography study. (1993) (266)
A proposed staging system for amyotrophic lateral sclerosis (2012) (263)
Relation between cognitive dysfunction and pseudobulbar palsy in amyotrophic lateral sclerosis. (1997) (253)
Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study (2010) (247)
Functional magnetic resonance imaging of verbal fluency and confrontation naming using compressed image acquisition to permit overt responses (2003) (243)
Visuospatial memory deficits at different stages of Parkinson's disease (1993) (243)
Hippocampal and neocortical ubiquitin-immunoreactive inclusions in amyotrophic lateral sclerosis with dementia (1992) (243)
A prospective study of quality of life in ALS patients treated with noninvasive ventilation (2001) (238)
Biomarkers in amyotrophic lateral sclerosis (2009) (231)
Charcot-Marie-Tooth disease neurofilament mutations disrupt neurofilament assembly and axonal transport. (2002) (211)
Neurofilament heavy chain side arm phosphorylation regulates axonal transport of neurofilaments (2003) (200)
Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis (2009) (197)
Good practice in the management of amyotrophic lateral sclerosis: Clinical guidelines. An evidence‐based review with good practice points. EALSC Working Group (2007) (197)
NEK1 variants confer susceptibility to amyotrophic lateral sclerosis (2016) (195)
Glutamate Slows Axonal Transport of Neurofilaments in Transfected Neurons (2000) (182)
Extramotor involvement in ALS: PET studies with the GABA(A) ligand [(11)C]flumazenil. (2000) (176)
The effect of non-invasive positive pressure ventilation (NIPPV) on cognitive function in amyotrophic lateral sclerosis (ALS): a prospective study (2001) (161)
Clinical care of patients with amyotrophic lateral sclerosis (2007) (158)
The sex ratio in amyotrophic lateral sclerosis: A population based study (2010) (152)
Is language impairment more common than executive dysfunction in amyotrophic lateral sclerosis? (2012) (148)
Cu/Zn superoxide dismutase gene mutations in amyotrophic lateral sclerosis: correlation between genotype and clinical features. (1996) (147)
Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. (2006) (147)
Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study (2018) (145)
Flail arm syndrome: a distinctive variant of amyotrophic lateral sclerosis (1998) (141)
Copper/zinc superoxide dismutase 1 and sporadic amyotrophic lateral sclerosis: Analysis of 155 cases and identification of novel insertion mutation (1997) (140)
The effect of noninvasive ventilation on ALS patients and their caregivers (2006) (140)
Cognitive change in ALS (2005) (136)
Predictors of psychological distress in carers of people with amyotrophic lateral sclerosis: a longitudinal study (2006) (130)
Genetic Variants of the α-Synuclein Gene SNCA Are Associated with Multiple System Atrophy (2009) (122)
The psychological impact of motor neurone disease (1994) (119)
Respiratory aspects of neurological disease (1999) (118)
Nutritional management in MND/ALS patients: an evidence based review (2004) (117)
A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. (1998) (116)
The anatomy of cognitive impairment in amyotrophic lateral sclerosis: More than frontal lobe dysfunction (2012) (110)
Cough augmentation in amyotrophic lateral sclerosis (2003) (102)
Amyotrophic lateral sclerosis with sensory neuropathy: part of a multisystem disorder? (2006) (101)
Living with motor neurone disease: lives, experiences of services and suggestions for change. (2005) (101)
Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis (2017) (99)
Cytoskeletal abnormalities in motor neuron disease. An immunocytochemical study. (1989) (99)
Recent advances in amyotrophic lateral sclerosis (2000) (98)
Phosphorylation of neurofilament heavy chain side-arms by stress activated protein kinase-1b/Jun N-terminal kinase-3. (2000) (97)
Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale (2014) (97)
Two families with familial amyotrophic lateral sclerosis are linked to a novel locus on chromosome 16q. (2003) (95)
ALS2/Alsin Regulates Rac-PAK Signaling and Neurite Outgrowth* (2005) (93)
p35/cdk5 binds and phosphorylates beta-catenin and regulates beta-catenin/presenilin-1 interaction. (2001) (90)
Symptoms and Quality of Life in Late Stage Parkinson Syndromes: A Longitudinal Community Study of Predictive Factors (2012) (89)
Cortical function in progressive lower motor neuron disorders and amyotrophic lateral sclerosis (1994) (89)
Symptom prevalence, severity and palliative care needs assessment using the Palliative Outcome Scale: A cross-sectional study of patients with Parkinson’s disease and related neurological conditions (2013) (86)
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trial (2009) (85)
Safety, Pharmacokinetic, and Functional Effects of the Nogo-A Monoclonal Antibody in Amyotrophic Lateral Sclerosis: A Randomized, First-In-Human Clinical Trial (2014) (85)
Truncated forms of the androgen receptor are associated with polyglutamine expansion in X-linked spinal and bulbar muscular atrophy. (1998) (84)
Relationships between Lewy bodies and pale bodies in Parkinson's disease (2004) (82)
Altered cortical activation during a motor task in ALS (2000) (82)
Amyotrophic lateral sclerosis in an urban setting (2006) (82)
Behavioural and emotional symptoms of apathy are associated with distinct patterns of brain atrophy in neurodegenerative disorders (2013) (81)
Disease Severity and Progression in Progressive Supranuclear Palsy and Multiple System Atrophy: Validation of the NNIPPS – PARKINSON PLUS SCALE (2011) (80)
Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials (2014) (78)
Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome (2019) (77)
Regional changes of ciliary neurotrophic factor and nerve growth factor levels in post mortem spinal cord and cerebral cortex from patients with motor disease (1995) (75)
Neurofibrillary tangles in dementia pugilistica are ubiquitinated. (1991) (74)
Excitotoxicity in ALS (1996) (72)
Amyotrophic lateral sclerosis: glutamate dehydrogenase and transmitter amino acids in the spinal cord. (1991) (71)
A patient with reflex myoclonus and muscle rigidity: "jerking stiff-man syndrome". (1980) (71)
The emotional lability questionnaire: a new measure of emotional lability in amyotrophic lateral sclerosis (1999) (70)
Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials (2017) (69)
Cytoskeletal pathology in motor neuron diseases. (1991) (69)
Diffusion Tensor Imaging of Parkinson’s Disease, Multiple System Atrophy and Progressive Supranuclear Palsy: A Tract-Based Spatial Statistics Study (2014) (68)
Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment. (1997) (66)
Longitudinal predictors of psychological distress and self-esteem in people with ALS (2006) (65)
Latent Cluster Analysis of ALS Phenotypes Identifies Prognostically Differing Groups (2009) (65)
Presynaptic and postsynaptic striatal dopaminergic function in neuroacanthocytosis: A positron emission tomographic study (1991) (63)
A clinical tool for predicting survival in ALS (2016) (63)
Identification of a Novel, Membrane-Associated Neuronal Kinase, Cyclin-Dependent Kinase 5/p35-Regulated Kinase (2003) (63)
A positron emission tomography study of frontal lobe function (verbal fluency) in amyotrophic lateral sclerosis (1995) (62)
Analysis of chromosome 5q13 genes in amyotrophic lateral sclerosis: Homozygous naip deletion in a sporadic case (1996) (62)
Ethical and clinical issues in the use of home non-invasive mechanical ventilation for the palliation of breathlessness in motor neurone disease (1999) (62)
The validation of El Escorial criteria for the diagnosis of amyotrophic lateral sclerosis: A clinicopathological study (1995) (61)
Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial (2004) (61)
Involvement of the amygdala, dentate and hippocampus in motor neuron disease (1995) (60)
Low index-to-ring finger length ratio in sporadic ALS supports prenatally defined motor neuronal vulnerability (2011) (60)
Association of a Locus in the CAMTA1 Gene With Survival in Patients With Sporadic Amyotrophic Lateral Sclerosis. (2016) (58)
Electrical injury and amyotrophic lateral sclerosis: a systematic review of the literature (2006) (57)
Characterizing axonal myelination within the healthy population: a tract-by-tract mapping of effects of age and gender on the fiber g-ratio (2017) (56)
C9orf72 and UNC13A are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: A genome‐wide meta‐analysis (2014) (56)
Neurite orientation and dispersion density imaging (NODDI) detects cortical and corticospinal tract degeneration in ALS (2018) (55)
Distribution of NADPH-diaphorase positive cells in the rat brain. (1990) (54)
Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases (2018) (52)
An Overview of MicroRNAs as Biomarkers of ALS (2019) (52)
Mapping of Gene Expression Reveals CYP27A1 as a Susceptibility Gene for Sporadic ALS (2012) (52)
The Role of Copy Number Variation in Susceptibility to Amyotrophic Lateral Sclerosis: Genome-Wide Association Study and Comparison with Published Loci (2009) (52)
Comparison of the King’s and MiToS staging systems for ALS (2017) (51)
Cyclin dependent kinase-5 (CDK-5) phosphorylates neurofilament heavy (NF-H) chain to generate epitopes for antibodies that label neurofilament accumulations in amyotrophic lateral sclerosis (ALS) and is present in affected motor neurones in ALS (1999) (51)
Cortical Thickness, Surface Area and Volume Measures in Parkinson's Disease, Multiple System Atrophy and Progressive Supranuclear Palsy (2014) (49)
p38alpha stress-activated protein kinase phosphorylates neurofilaments and is associated with neurofilament pathology in amyotrophic lateral sclerosis. (2004) (49)
Defining survival as an outcome measure in amyotrophic lateral sclerosis. (2009) (48)
Entristar skin-level gastrostomy tube: primary placement with radiologic guidance in patients with amyotrophic lateral sclerosis. (2004) (48)
Cortical involvement in four cases of primary lateral sclerosis using [11C]-flumazenil PET (2007) (48)
A common haplotype within the PON1 promoter region is associated with sporadic ALS (2008) (47)
Diffusion tensor imaging in sporadic and familial (D90A SOD1) forms of amyotrophic lateral sclerosis. (2009) (46)
Clinical trials in ALS: an overview. (2001) (45)
New aspects of the pathology of neurodegenerative disorders as revealed by ubiquitin antibodies (2004) (45)
Motor neurone disease: A review of its emotional and cognitive consequences for patients and its impact on carers (1999) (44)
A RAPID SCREENING BATTERY TO IDENTIFY FRONTAL DYSFUNCTION IN PATIENTS WITH ALS (2007) (44)
Trouble on the pitch: are professional football players at increased risk of developing amyotrophic lateral sclerosis? (2005) (43)
Automated, High Accuracy Classification of Parkinsonian Disorders: A Pattern Recognition Approach (2013) (42)
Patients' health-related quality-of-life and health state values for motor neurone disease/amyotrophic lateral sclerosis (2003) (41)
Androgen‐induced up‐regulation of tubulin isoforms in neuroblastoma cells (2001) (41)
Geographical Clustering of Amyotrophic Lateral Sclerosis in South-East England: A Population Study (2008) (40)
Altered patterns of cortical activation in ALS patients during attention and cognitive response inhibition tasks (2011) (40)
Psychological as well as illness factors influence acceptance of non-invasive ventilation (NIV) and gastrostomy in amyotrophic lateral sclerosis (ALS): A prospective population study (2014) (39)
Cortical activation during motor imagery is reduced in Amyotrophic Lateral Sclerosis (2007) (39)
Enterovirus infection of the central nervous system of humans: lack of association with chronic neurological disease. (1996) (38)
Indicators and Prevalence of Malnutrition in Motor Neurone Disease (1998) (37)
Erratum: Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease (The Lancet, vol. 339/8806 (1375-1377)) (1992) (36)
Exploring the temporal nature of hemodynamic responses of cortical motor areas using functional MRI (1998) (36)
Syntactic processing as a marker for cognitive impairment in amyotrophic lateral sclerosis (2015) (36)
The benefit of evolving multidisciplinary care in ALS: a diagnostic cohort survival comparison (2017) (35)
Mitochondrial abnormalities and low grade inflammation are present in the skeletal muscle of a minority of patients with amyotrophic lateral sclerosis; an observational myopathology study (2014) (35)
Spinal cord trauma in man: studies of phosphorylated neurofilament and ubiquitin expression. (1990) (34)
Cognitive deficits in non-demented amyotrophic lateral sclerosis patients: a neuropsychological investigation (1995) (33)
Genetic and epigenetic studies of amyotrophic lateral sclerosis (2013) (29)
Neurotrophin-3-like immunoreactivity and Trk C expression in human spinal motoneurones in amyotrophic lateral sclerosis (1997) (29)
Symptom Prevalence among People Affected by Advanced and Progressive Neurological Conditions—a Systematic Review (2007) (29)
Neuroprotective effect of free radical scavengers on β-N-oxalylamino-l-alanine (BOAA)-induced neuronal damage in rat hippocampus (1994) (28)
A new MRI rating scale for progressive supranuclear palsy and multiple system atrophy: validity and reliability (2011) (28)
Decision Making About Gastrostomy and Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (2016) (28)
Late-onset Tay–Sachs disease (2017) (28)
Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis (2014) (28)
β-amyloid precursor protein fragments and lysosomal dense bodies are found in rat brain neurons after ventricular infusion of leupeptin (1994) (27)
Neuronal damage induced by ß-N-oxalylamino-l-alanine, in the rat hippocampus, can be prevented by a non-NMDA antagonist, 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (1993) (27)
Marital relationships in amyotrophic lateral sclerosis (2010) (27)
Residual association at C9orf72 suggests an alternative amyotrophic lateral sclerosis-causing hexanucleotide repeat (2013) (26)
Ligand-dependent aggregation of polyglutamine-expanded androgen receptor in neuronal cells (2002) (26)
Rare genetic variation in UNC13A may modify survival in amyotrophic lateral sclerosis (2016) (26)
C9orf72 and UNC13A are shared risk loci for ALS and FTD: A genome-wide meta-analysis (2014) (26)
Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial (2020) (25)
Mushroom-cage gastrostomy tube placement in patients with amyotrophic lateral sclerosis: a 5-year experience in 104 patients in a single institution (2009) (25)
Imaging: MRS/MRI/PET/SPECT: Summary (2002) (24)
Variants in the ALS2 gene are not associated with sporadic amyotrophic lateral sclerosis (2003) (24)
Identification of a potential non-coding RNA biomarker signature for amyotrophic lateral sclerosis (2020) (23)
Imaging the brain during sniffing: a pilot fMRI study. (2009) (23)
Routes of excretion of neuronal lysosomal dense bodies after ventricular infusion of leupeptin in the rat: a study using ubiquitin and PGP 9.5 immunocytochemistry (1993) (22)
The moving ear syndrome: a focal dyskinesia. (1996) (22)
Emerging Magnetic Resonance Imaging Techniques and Analysis Methods in Amyotrophic Lateral Sclerosis (2018) (22)
Palliative care in motor neurone disease. (1995) (21)
Eating-derived pleasure in amyotrophic lateral sclerosis as a predictor of non-oral feeding (2012) (21)
Occasional essay: Upper motor neuron syndrome in amyotrophic lateral sclerosis (2020) (20)
Genome‐wide survey of copy number variants finds MAPT duplications in progressive supranuclear palsy (2019) (19)
Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic Lateral Sclerosis (LiCALS) [Eudract number: 2008-006891-31] (2011) (19)
Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial (2019) (19)
Chapter 13 Amyotrophic lateral sclerosis. (2007) (19)
Amino acids for amyotrophic lateral sclerosis / motor neuron disease. (2008) (19)
Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials (2019) (19)
Absence of cognitive, behavioral, or emotional dysfunction in progressive muscular atrophy (2006) (18)
Evidence of an environmental effect on survival in ALS (2014) (18)
Minocycline for patients with ALS (2008) (17)
Positron emission tomography (PET) – its potential to provide surrogate markers in ALS (2000) (17)
Debrisoquine hydroxylase gene polymorphism in Parkinson's disease and amyotrophic lateral sclerosis. (1995) (16)
The Economic Costs of Progressive Supranuclear Palsy and Multiple System Atrophy in France, Germany and the United Kingdom (2011) (15)
Gigaxonin is associated with the Golgi and dimerises via its BTB domain (2004) (15)
Magnetic resonance spectroscopic study of parkinsonism related to boxing. (1995) (15)
Predicting the future of ALS: the impact of demographic change and potential new treatments on the prevalence of ALS in the United Kingdom, 2020–2116 (2019) (15)
Alzheimer’s disease, amyotrophic lateral sclerosis, and transgenic mice (1998) (14)
Homozygosity analysis in amyotrophic lateral sclerosis (2013) (14)
Morphological differences of intraneuronal ubiquitin‐positive inclusions in the dentate gyrus and parahippocampal gyrus of motor neuron disease with dementia (2004) (14)
The effect of polyglutamine expansion in the human androgen receptor on its ability to suppress β-catenin-Tcf/Lef dependent transcription (2004) (14)
Motor neuron disease: Focusing the mind on ALS: updated practice parameters (2010) (13)
Superoxide dismutase activity in lymphoblastoid cells from motor neurone disease/amyotrophic lateral sclerosis (MND/ALS) patients (1995) (11)
The Molecular Pathology of Motor Neuron Disease (1995) (11)
Society for Neuroscience Abstracts (2001) (11)
Epilepsy as the presenting feature of neuroacanthocytosis in siblings (1992) (10)
Positron emission tomography (PET)--its potential to provide surrogate markers in ALS. (2000) (10)
Immunocytochemical studies of neurotrophins in cerebral motor cortex in Amyotrophic Lateral Sclerosis (1997) (10)
Legionella brain stem encephalopathy and peripheral neuropathy without preceding pneumonia. (1986) (10)
Evolution of white matter damage in amyotrophic lateral sclerosis (2020) (10)
Purkinje cell toxicity ofβ-aminopropionitrile in the rat (2005) (9)
Diffusion Tensor Imaging in Sporadic and Familial ( D 90 A SOD 1 ) Forms of Amyotrophic Lateral Sclerosis (2008) (9)
Expression of the human groEL stress-protein homologue in the brain and spinal cord (1993) (9)
Analysis of terms used for the diagnosis and classification of amyotrophic lateral sclerosis and motor neuron disease (2016) (9)
Facial Onset Sensory and Motor Neuronopathy (2020) (8)
Androgen-controlled specific gene expression in neuroblastoma cells (1995) (8)
Motor Neuron Disease: Biology And Management (2011) (7)
Purkinje cell toxicity of beta-aminopropionitrile in the rat. (1991) (6)
Nutritional care of patients with motor neurone disease (2005) (6)
Association of a Locus in the CAMTA 1 GeneWith Survival in PatientsWith Sporadic Amyotrophic Lateral Sclerosis (2016) (6)
WITHDRAWN: Amino acids for amyotrophic lateral sclerosis / motor neuron disease. (2008) (5)
Common variation at the LRRK2 locus is associated with survival in the primary tauopathy progressive supranuclear palsy (2020) (5)
Chapter 21 Disease-Modifying Therapies in Motor Neuron Disorders: The Present Position and Potential Future Developments (2003) (5)
Altered network stability in progressive supranuclear palsy (2021) (4)
Cortical function in progressive muscular atrophy and amyotrophic lateral sclerosis (1994) (4)
RILUZOLE AND AMYOTROPHIC LATERAL SCLEROSIS. AUTHORS' REPLY (1996) (4)
Regionality of disease progression predicts prognosis in amyotrophic lateral sclerosis (2015) (4)
Chapter 8 Spinobulbar muscular atrophy (Kennedy's disease). (2007) (4)
Riluzole and Motor Neurone Disease (2003) (3)
Neuroprotection and Natural History in Parkinson Plus Syndromes (NNIPPS): Design and progress report of a clinical trial of the efficacy and safety of riluzole in Progressive Supranuclear Palsy (PSP) and Multiple System Atrophy (MSA) (2002) (3)
Corrigendum: An Overview of MicroRNAs as Biomarkers of ALS (2019) (3)
Unusual Forms of Dementia (1994) (3)
A novel somatodendritic marker defined by a peptide derived from the ALS2 protein (2004) (2)
Cough Augmentation In Bulbar And Non-bulbar Motor Neuron Disease Patients (2001) (2)
A virtual user involvement forum for people living with motor neuron disease (2003) (2)
Neurite Orientation Dispersion and Density Imaging (NODDI) highlights axonal degeneration of the motor tracts as the core feature underlying Amyotrophic Lateral Sclerosis. (S53.008) (2017) (2)
Neuroprotection and natural history (multiple system atrophy and progressive supranuclear palsy) (2004) (2)
017 Apathy is associated with altered cortical activation in pre-frontal regions during self-initiated actions (2010) (1)
The challenges for policies and practices relating to MND health and social care. 13th International Symposium on ALS/ MND, Melbourne (2002) (1)
Building user involvement in motor neurone disease: key lessons. (2004) (1)
Erratum: Residual association of chromosome 9P21 SNPS with ALS after exclusion of C9ORF72 mutated cases (Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (2012) 13 (18)) (2013) (1)
Chapter 20. Amyotrophic Lateral Sclerosis (2008) (1)
Living with Motor Neuron Disease (1995) (1)
Clinical trials in pediatric ALS: a TRICALS feasibility study (2022) (1)
Frontal lobe dysfunction in amyotrophic lateral (1996) (1)
Protective effects of estrogens on polyglutamine-expanded androgen receptor aggregation in mice. (2003) (1)
MMT vs MVIC (2003) (1)
Using GFP-tagged neurofilament middle chain to investigate slow transport in cultured cortical neurons (2000) (1)
Validity and reliability of the German language SF-36 health survey in patients with amyotrophic lateral sclerosis (2002) (1)
Neurite Orientation Dispersion and Density Imaging (NODDI) demonstrates microstructural changes associated with Amyotrophic Lateral Sclerosis (2015) (1)
Baseline disease characteristics (2004) (1)
IMMUNO-MODULATION IN AMYOTROPHIC LATERAL SCLEROSIS - A PHASE II STUDY OF SAFETY AND ACTIVITY OF LOW DOSE INTERLEUKIN-2 (IMODALS study) (S3.006) (2017) (1)
The role of superoxide-dismutase in protection against DNA damage induction following ionising radiation. (1995) (0)
Advances in amyotrophic lateral sclerosis - Papers from the 10th International Symposium on Amyotrophic Lateral Sclerosis/Motor Neuron Disease held in Vancouver on November 15-17 November, 1999 - Preface (2000) (0)
Mitochondrial abnormalities and low grade inflammation are present in the skeletal muscle of a minority of patients with amyotrophic lateral sclerosis; an observational myopathology study (2014) (0)
Chapter 63 – Sporadic Motor Neuron Degeneration (2005) (0)
[C-11]-WAY100635 PET: A surrogate marker for MND? (2003) (0)
Motor neuron disease presenting following prolonged diaphragm paralysis (2006) (0)
Cortical localisation of neuropsychological impairment in amyotrophic lateral sclerosis (ALS): An [C-11] Flumazenil PET study (2005) (0)
Atlas of the Human Brain and Spinal Cord (1984) (0)
Motor Neuron Disease: Amyotrophic Lateral Sclerosis 98 (2013) (0)
Preface (2001) (0)
Preface (2000) (0)
New insights into amyotrophic lateral sclerosis using quantitative magnetization transfer (qMT) (2017) (0)
UvA-DARE ( Digital Academic Repository ) Two families with familial amyotrophic lateral sclerosis are linked to a novel locus on chromosome (2017) (0)
Picture quiz: Muscle weakness and wasting (2007) (0)
Is cortical excitability abnormal in mnd? A study using pharmacological fMRI (2007) (0)
830 The role of superoxide dismutase in protection against radiation-induced DNA damage (1995) (0)
Mean plasma ozanezumab concentration-time profiles following single (A) or two (B) IV infusions of ozanezumab. (2014) (0)
PAW22 Does cortical atrophy take place after basal ganglia damage in multiple system atrophy and progressive supranuclear palsy? (2010) (0)
Chapter 67 – Inherited Motor Neuron Degeneration (2005) (0)
13th International Sysmposium on ALS/ MND (2002) (0)
3 Famiiial Motor Neuron Disease (1995) (0)
Programme for the 112th Meeting of the British Neuropathological Society, Institute of Child Health, London, UK, 5–7 January 2011 (2011) (0)
Altered cortical activation in amyotrophic lateral sclerosis (ALS) differs in motor and extra-motor regions (2006) (0)
Effect of the Kennedy Mutation of the Androgen Receptor on Gene Expression in Neuroblastoma Cells (1996) (0)
Diffusion tensor imaging demonstrates differential involvement of brain structures in MSA and PSP (2004) (0)
A simple FMRI paradigm for mapping the major components of the human motor system (1997) (0)
Neurochemistry of Motor Neuron Disease (1995) (0)
University of Groningen Mapping of Gene Expression Reveals CYP 27 A 1 as a Susceptibility Gene for Sporadic (2012) (0)
Motor Neuron Disease and Its Management (1999) (0)
Diffusion tensor imaging reveals white matter differences between sporadic and familial forms of amyotrophic lateral sclerosis (2008) (0)
Modern Approaches to the Dementias. Part I: Etiology and Pathophysiology. Part II: Clinical and Therapeutic (1986) (0)
Involving motor neurone disease users in practice and policy development (2002) (0)
CORRELATION ANALYSIS OF NEURITE ORIENTATION DISPERSION & DENSITY IMAGING IN MND (2016) (0)
Special Issue - Advances in Amyotrophic Lateral Sclerosis - Preface (2001) (0)
Quality of life in patients with motor neuron disease treated with non-invasive ventilation (NIPPV) (2001) (0)
The D90A SOD1 mutation in amyotrophic lateral sclerosis: Why are the Scandinavians protected? (2001) (0)
Journal of the Neurological Sciences: Preface (2001) (0)
ABNORMALITIES OF RESTING AND ACTIVATED CORTICAL BLOOD-FLOW IN AMYOTROPHIC-LATERAL-SCLEROSIS (ALS) AND PROGRESSIVE MUSCULAR-ATROPHY (PMA) (1993) (0)
Progression of atypical parkinsonian syndromes: PROSPECT-M-UK study implications for clinical trials. (2023) (0)
Building a virtual community in MND (2002) (0)
CORTICAL MECHANISMS UNDERLYING THE PERCEPTION OF PHANTOM LIMBS IN HUMAN AMPUTEES (1994) (0)
P20 Frontal white matter connections and cognitive change in amyotrophic lateral sclerosis: a DTI-tractography study (2012) (0)
A Data-Driven Characterisation of the Evolution of White Matter Damage in Amyotrophic Lateral Sclerosis (2020) (0)
White matter maps showing regions of significant decreased fractional anisotropy and increased mean diffusivity in MSA patients when compared to healthy controls and PD (Bonferroni corrected alpha = 0.0167). (2014) (0)
DS1.1 Motorneurone degeneration: ALS and its clinical variants (2006) (0)
MATTERS ARISING (1995) (0)
White matter regions of fractional anisotropy changes between PSP, MSA, PD and HC. (2014) (0)
Motor neurone disease. (1976) (0)
Mutations in ANXA11 cause familial and sporadic amyotrophic lateral sclerosis (2017) (0)
Cross-sectional clinical description of a large prospective cohort of patients with progressive supranuclear palsy or multiple system atrophy: The NNIPPS project (2003) (0)
Neurodegenerative Diseases: An approach to the patient with motor neuron dysfunction (2005) (0)
Cyclin dependent kinase 5 (CDK5) and neurodegeneration. (1999) (0)
Diffusion tensor imaging demonstrates differential involvement of brainstem structures in progressive supranuclear palsy but not idiopathic Parkinson's disease (2004) (0)
Disruption of thalamo-cortical loops predicts executive dysfunction in PSP (2006) (0)
FP47-TH-05 Assessment of palliative care needs in people affected by advanced Parkinson's disease and related disorders (2009) (0)
Cellular phosphorylation of neurofilament heavy-chain by multiple kinases (2000) (0)
Reply to: Early white matter changes on diffusion tensor imaging in amyotrophic lateral sclerosis (2020) (0)
LITHIUM CARBONATE IS NOT BENEFICIAL FOR PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS: RESULTS OF THE LICALS TRIAL [EUDRACT NUMBER: 2008-006891-31] (2012) (0)
Natural History and Neuroprotection in Parkinson Plus Syndromes Parkinson Plus Scale (2014) (0)
NR1: PATIENTS' REPORTED HEALTH STATUS AND UTILITIES FOR AMYOTROPHIC LATERAL SCLEROSIS (2000) (0)
Neural control of voluntary breathing: Insight from functional neuroimaging (2006) (0)
Neurite orientation dispersion and density imaging (NODDI) indices correlate with clinical markers of disease severity in amyotrophic lateral sclerosis (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Peter Nigel Leigh?

Peter Nigel Leigh is affiliated with the following schools:

Peter Nigel Leigh's Academic­Influence.com Rankings